[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652247":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":41,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"RAI-R DTC Cohort",null,"Adult patients diagnosed with RAI-R DTC.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100652247","a-real-world-study-of-second-line-therapies-among-radioiodine-refractory-differentiated-thyroid-cancer-rai-r-dtc-patients-100652247",false,"NCT07770074","A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients","Real-World Evidence of Second-line Systematic Therapy With BRAF V600E Mutation-guided Dabrafenib + Trametinib or Mutation-agnostic Multi-targeted Tyrosine Kinase Inhibitors (MKIs) in Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC)","Inclusion criteria:\n\n* Patients with a diagnosis of thyroid cancer.\n* Patients with a pathological confirmation of differentiated thyroid cancer (DTC).\n* Patients who initiated either MKI monotherapy (lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib) or D+T combination therapy between January 1, 2019 and December 31, 2025 (or the data cutoff date).\n* Patients with no curative-intent thyroid cancer surgery within 3 months after initiation of systematic therapy.\n\nExclusion criteria:\n\n• Patients participating in a blinded interventional clinical trial, or any open-label observational study involving D+T or MKI, during the study period.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years","100 Years",{"count":35,"type":36},200,"ESTIMATED","OBSERVATIONAL","This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.",[40],"Radioiodine-refractory Differentiated Thyroid Cancer",[40,42,43,44,45],"BRAF V600E mutation","Dabrafenib","Trametinib","Second-line systematic therapy","NOT_YET_RECRUITING","2026-08-10",{"date":49,"type":50},"2026-08-18","ACTUAL",{"date":52,"type":36},"2026-10-08",{"date":54,"type":36},"2026-10-31",{"name":14,"class":6}]